> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Pfizer Xeljanz Once-daily Tablet
- URL: https://www.fdaweb.com/fda-oks-pfizer-xeljanz-once-daily-tablet/
- Published: 2016-02-25T12:00:00.000Z
- Updated: 2026-09-15T02:38:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134885

> FDA has approved a Pfizer NDA for Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate. Pfizer says Xeljanz XR is the first once-daily oral RA treatment in the Janus kinase inhibitors drug class. The submission was based on data from a clinical pharmacology program designed to demonstrate equivalence in key pharmacokinetic parameters to Xeljanz 5 mg twice daily, according to the company.